Our 2023 report on the 340B Drug Discount Program highlights significant growth and concerns regarding the program’s current implementation. The report emphasizes issues such as financial gains by certain entities, lack of transparency and the need for reforms to ensure that the program benefits the intended vulnerable patient populations.
View the full report here.